FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer
Share:
Listens: 0
About
FDA medical oncologists discuss the January 12, 2018, approval of olaparib, the first PARP inhibitor approved for the treatment of patients with metastatic breast cancer with a germline BRCA mutation.
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
Science
FDA medical oncologists discuss the January 12, 2018, approval of olaparib, the first PARP inhibitor approved for the treatment of patients with metastatic breast cancer with a germline BRCA mutation.